Finally! An analyst coverage! I have shared this small-ish China-based drug development firm some time ago. Its volume has historically been low, but still an improvement over nearly a decade ago when I started a position. The coverage focuses solely on weight loss drugs development. As mentioned in my earlier post, Ascletis Pharma is not just a one-trick pony, but weight loss is a great start and on path to success (Most advanced of all developments with a patent to boot). I might be looking to add to my positions after taking some profits in the past. The current investment thesis just got better...
Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with "Buy" Rating, Sets Target Price at HK$18.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
